The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: N4 Pharma hails "encouraging" siRNA research

Thu, 07th Dec 2023 18:28

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Etablissements Maurel & Prom SA, a Paris-based, energy industry-focused company, says it is moving closer to acquiring Wentworth. Explains that it has signed an agreement with the Tanzania Petroleum Development Corporation, which is structured as a 'call option' and allows Tanzania Petroleum to increase its ownership in the production interest by up to 20%. Wentworth has arranged for the Jersey Court to consider and possibly sanction the scheme at a hearing on December 19. Following this date, M&P will take ownership of Wentworth and acquire its 32% direct and indirect interest in Mnazi Bay. Subsequent to the closing of the Acquisition, M&P expects Tanzania Petroleum this call option, meaning that M&P will hold a 60% ownership in Mnazi Bay, and Tanzania Petroleum will hold 40%. M&P says the joint operating agreement will be changed to reflect these new partnership conditions. Adds that it will fund the acquisition with the GBP63 millio placed in escrow.

----------

N4 Pharma PLC - Derbyshire-based specialist pharmaceutical company focused on a delivery system for oncology, gene therapy and vaccines - Says that its work-to-date on its ongoing in vitro small interfering ribonucleic acid research, or siRNA, is "very encouraging", and shows that Nuvec has "considerable potential" to be able to knockdown two independent pathways leading to "more effective "cancer treatments. Explains that it has been investigating the ability of Nuvec nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. After confirming dual loading of Nuvec, N4 then tested the effect of BRD4 combined with EGFR and PLK1 combined with EGFR on knockdown and cell viability. Says that when when loaded together there was an interaction which resulted in a reduction in knockdown of EGFR receptor, though the reduction on cell viability was retained. It is now exploring varying the amount of each siRNA loaded on Nuvec, and also looking at how low the dose can be reduced to still achieve a functional cell inhibition endpoint. In terms of strategy moving forwards, says that that the precise combinations of siRNA, both in terms of target and concentration of siRNA, will vary depending in which cell type they are tested in.

----------

Software Circle PLC - Manchester-based printing and software company - Regarding the sale of Works Manchester Ltd, says that Works Manchester has filed a notice of intention to appoint administrators. This follows an earlier announcement in June, when Software said it had not received the first instalment of deferred consideration from Rymack Sign Solutions Ltd to buy Works Manchester. Further, due to reduced confidence of receiving payment of any deferred consideration from Rymack, the carrying value of the GBP2.81 million due under the sale and purchase agreement has been reduced to GBP350,000. Software is in the process of taking steps to recover the sums due, and says it will update the market again in due course. Adds that the Nettl Systems management team have been making arrangements with alternative suppliers so that continuity of supply is in place for products available through the Nettl Systems platform.

----------

Ecofin US Renewables Infrastructure Trust PLC - Investor in US renewable energy assets - Expects its Whirlwind Energy wind asset in in Floydada, Texas to reenergise in mid-December, after moving "significantly closer" to coming back online. Says that AEP, the owner of the Matador and Paducah substations, has now finished testing a new transmission line past Matador to Paducah. Adds that the first payment on its business interruption coverage has now been received and further payments are scheduled to follow, "substantially mitigating lost revenue". Meanwhile, the Ellis Road solar farm in Westminster, Massachusetts is back online, following a rodent infestation. Finally, says that progress continues to be made on a previously announced strategic review. Says there can be no certainty as to the outcome of the review or any asset sale process, nor whether any potential transaction or transactions arising could be successfully completed.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
9 Mar 2023 14:32

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Nov 2022 11:16

AIM WINNERS & LOSERS: Parsley Box to exit AIM as shares wilt since IPO

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
18 Nov 2022 11:02

N4 Pharma plummets on broker offer to raise up to GBP1 million

(Alliance News) - N4 Pharma PLC shares plummeted on Friday, after it raised GBP1.0 million through a placing of 50.0 million shares and announced a broker offer to raise up to GBP1.0 million.

Read more
18 Nov 2022 08:11

N4 Pharma shares tumble following placing, broker offer announcement

(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.

Read more
1 Nov 2022 17:06

IN BRIEF: N4 Pharma expands patent application claims for Nuvec

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Provides a patent application update for Nuvec.

Read more
4 Oct 2022 13:32

N4 Pharma reports success in recent 'Nuvec' testing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.

Read more
4 Oct 2022 11:19

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
4 Oct 2022 10:38

N4 Pharma announces successful test in next stage of Nuvec development

(Alliance News) - N4 Pharma PLC on Tuesday announced successful in vitro testing of Nuvec when loaded with two small interfering siRNA probes.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
29 Sep 2022 15:09

EARNINGS UPDATES: Crestchic raises outlook on record year-to-date

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Sep 2022 12:11

N4 Pharma reduces losses as Nuvec development continues

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.

Read more
14 Sep 2022 12:03

IN BRIEF: N4 completes testing on loading Nuvec drug with siRNA probes

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Completes initial testing on loading its Nuvec treatment with two generic siRNA probes at the same time. siRNA can prevent cells from communicating, potentially preventing cancer cells from replicating. N4 are now undertaking experiments using siRNA sequences against known oncology targets. This includes in vitro using a lung cancer cell line and, after that, in vivo studies in mice. Chief Executive Officer Nigel Theobald said: "We have now identified a very strong commercial point of difference for Nuvec in that it can be successfully loaded with at least two siRNA genes".

Read more
15 Jul 2022 21:26

TRADING UPDATES: Premier Miton assets dip; Challenger Energy CFO quits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
15 Jul 2022 13:23

N4 Pharma upbeat on latest tumour suppression study data

(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.